24/7 BIOPHARMA - issue 1 / October 2024

NEWS

PROCOS S.P.A. continues to expand: updates about recent investments & technology

PROCOS S.P.A., announced its progress on the expansion of its current cGMP manufacturing facility with the addition of a new building named R11. This state-of-the-art building, which will be fully commissioned in 2 phases, is ready for the installation of equipment for Phase I, which has a total investment of 65M Euro. R11 represents PROCOS’ significant organic growth in the small molecule CDMO sector as this new building will house 4 multipurpose lines focusing on small scale volumes with approximately 20, 1000 – 6000L reactors, 4 centrifuges and

additional drying capacity with the intention to support low volume, high value complex molecules and Clinical Phase I/II/III materials. This Phase I investment is expected to add another 73 cubic meters of manufacturing capacity. The equipment installation is ongoing, and qualification is expected in 2025, with approval and launch in 2026. “Our global partners have expressed sincere excitement about the new R11 building, especially when they have the opportunity to see the progress while visiting PROCOS on-site. It is amazing the draw for the small-scale volume capacity needs

because of the increased number of NCE programs PROCOS is engaged in are for rare disease or more complex molecules, compared to the past,” said Simone Manzini, Business Development Manager, Custom Synthesis. PROCOS continues to map out Phase II of this expansion which should include 15 reactors, 3 centrifuges and other unique drying capabilities. In total, at the completion of Phase I and Phase II, PROCOS anticipates a total capacity increase of 25%, reaching total output of over 700 cubic meters and upwards of 350 metric tons of total API output in the future.